Research Article
The Role of Serum Adiponectin for Outcome Prediction in Patients with Dilated Cardiomyopathy and Advanced Heart Failure
Table 1
Baseline characteristics and treatment of patients.
| | Parameter | Value | Total number of cases |
| | Sex | M: 45 (78.95%)
F: 12 (21.05%) | 57 | | NYHA class | | 55 | | I | 1 (1.81%) | | | II | 5 (9.09%) | | III | 38 (69.09%) | | IV | 11 (20.01%) | | iDCM | 30 (55.56%) | 55 | | Medications received | | | | ACE inhibitors | 31 (54%) | 57 | | Diuretics and mineralocorticoids receptor blockers | 55 (96%) | 57 | | ß-Blockers | 52 (91%) | 57 | | Digitalis (in atrial fibrillation) | 18 (32%) | 57 | | Anticoagulation (atrial fibrillation, EF < 40%) | 33 (58%) | 57 | | Antiarrhythmic (class III: amiodarone) | 10 (18%) | 57 |
|
|
iDCM: inflammatory dilated cardiomyopathy, ACE: angiotensin converting enzyme.
|
